Abstract
Those of us who see patients with cardiovascular disorders frequently use antiplatelet and anticoagulant agents; the common agents are aspirin, clopidogrel, and warfarin. This editorial is a personal viewpoint about commonly used drugs, not so commonly used drugs, and drugs that are yet to be used clinically. Copyright © 2010 Wiley Periodicals, Inc.
Full Text
The Full Text of this article is available as a PDF (831.3 KB).
References
- 1. Mega JL, Close SI, Wiviott SD, et al. Cytochrome P‐450 polymorphisms and response to Clopidogrel. N Engl J Med 2009; 360: 354–62. [DOI] [PubMed] [Google Scholar]
- 2. Hirsch J. Oral Anticoagulants. N Engl J Med 2008; 358: 2218–2230.18499566 [Google Scholar]
- 3. Wiviott DS, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with actute coronary syndromes. N Engl J Med 2007; 357: 2001–15. [DOI] [PubMed] [Google Scholar]
- 4. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med September 17, 2009; 361: 1139. [DOI] [PubMed] [Google Scholar]
- 5. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med September 10, 2009; 361: 1045. [DOI] [PubMed] [Google Scholar]